Skip to content
Est. 1998 proudly celebrating our 27th year of championing American business
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Nyxoah SA

$1.39 -4.14% NASDAQ: NYXH · 15-min delayed
  • Public · NASDAQ: NYXH
  • 154 employees
$64.8MMarket cap
154Employees
NYXHNASDAQ
2021IPO

About Nyxoah SA

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Market cap
$64.8M
NASDAQ: NYXH
$1.39 -4.14%

15-minute delayed · data by Polygon.io

Past year

$1.39 $8.32

52-week range

Market cap
$64.8M
Shares outstanding
46.6M
Open
Day range
Prev close
Volume
IPO date
Mar 5, 2021

Market data by Polygon.io · prices are 15-minute delayed

Auto-generated

At a glance

  • Trading 83% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Nyxoah SA.

Write a review
Newsroom

News about Nyxoah SA

News & sentiment via Polygon.io

Explore

Similar companies

Browse all →